Biofrontera Inc. (BFRIW)
BFRIW Stock Price Chart
Explore Biofrontera Inc. interactive price chart. Choose custom timeframes to analyze BFRIW price movements and trends.
BFRIW Company Profile
Discover essential business fundamentals and corporate details for Biofrontera Inc. (BFRIW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
29 Oct 2021
Employees
92.00
Website
https://www.biofrontera-us.comCEO
Hermann Luebbert
Description
Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. Its product lineup features Ameluz, a prescription drug employed with the BF-RhodoLED lamp series for photodynamic therapy. This treatment is designed for both localized and broader area management of mild-to-moderate actinic keratosis on the face and scalp. Additionally, the company offers Xepi, a topical, non-fluorinated quinolone that functions by inhibiting bacterial growth to treat impetigo. Established in 2015, Biofrontera Inc. is headquartered in Woburn, Massachusetts.
BFRIW Financial Timeline
Browse a chronological timeline of Biofrontera Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 Aug 2026
EPS estimate is -$0.11, while revenue estimate is $9.50m.
Earnings released on 14 May 2026
EPS came in at -$0.41 falling short of the estimated -$0.12 by -256.52%, while revenue for the quarter reached $10.08m , missing expectations by -1.62%.
Earnings released on 19 Mar 2026
EPS came in at $0.48 surpassing the estimated $0.20 by +146.15%, while revenue for the quarter reached $17.10m , beating expectations by +5.88%.
Earnings released on 12 Nov 2025
EPS came in at -$0.62 falling short of the estimated -$0.58 by -6.38%, while revenue for the quarter reached $6.99m , missing expectations by -0.17%.
Earnings released on 13 Aug 2025
EPS came in at -$0.57 falling short of the estimated -$0.42 by -35.55%, while revenue for the quarter reached $9.03m , beating expectations by +8.80%.
Earnings released on 15 May 2025
EPS came in at -$0.47 falling short of the estimated -$0.22 by -120.29%, while revenue for the quarter reached $8.59m , missing expectations by -18.60%.
Earnings released on 30 Sept 2023
EPS came in at -$0.00 , while revenue for the quarter reached $8.90m .
Earnings released on 30 Jun 2023
EPS came in at -$0.01 , while revenue for the quarter reached $5.85m .
Earnings released on 31 Mar 2023
EPS came in at -$0.28 , while revenue for the quarter reached $8.73m .
Earnings released on 31 Dec 2022
Revenue for the quarter reached $10.14m .
BFRIW Stock Performance
Access detailed BFRIW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
